A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC

Sponsor
Haruhiko Fukuda
Study ID
NCT00144989
Phase
PHASE3
Status
Completed

Conditions

  • Small-Cell-Lung Cancer

Eligibility Criteria

Sex
ALL
Age
20 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To evaluate the role of 3 cycles of irinotecan and cisplatin for patients with limited-stage small-cell lung cancer who received one course of etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic irradiation.

Key Dates

Start date
Sep 30, 2002
Status verified
Sep 2016
Primary completion
Sep 30, 2011
Completion
Sep 30, 2011

Study Design

Enrollment
281 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: 1
    Etoposide and cisplatin after chemoradiotherapy
  • Experimental: 2
    Irinotecan and cisplatin after chemoradiotherapy

Primary Outcome Measure

overall survival [ Time Frame: during the study conduct ]